Initially, anti-PD-1 was thought to impact T cell effector function by releasing inhibition on exhausted PD-1+ CD8 TILs, via blocking interactions with PD-L1-expressing tumor cells or intratumoral leukocytes such as macrophages and MDSCs (72). The gene discussed is CD8A; the disease is neoplasm.